| NCT02040298 | Multiple Sclerosis, Relapsing-Remitting | Drug: Clemastine|Drug: Placebo | University of California, San Francisco | Phase 2 | 2014-01-01 | 2016-04-14 |
| NCT02521311 | Optic Neuritis | Drug: Clemastine|Drug: Placebo | University of California, San Francisco | Phase 2 | 2016-08-01 | 2017-03-13 |
| NCT02613091 | Healthy Subjects | Drug: Clemastine fumarate | University of California, San Francisco | Phase 1 | 2016-04-01 | 2016-11-02 |
| NCT00913549 | Allergy | Drug: Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)|Drug: Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.) | Sandoz | Phase 1 | 1989-12-01 | 2009-06-03 |
| NCT01239719 | Allergy|Dermatitis | Drug: Dexamethasone + clemastine|Drug: Dexamethasone | Azidus Brasil | Phase 3 | 2011-03-01 | 2011-01-27 |
| NCT01257061 | Eczema | Drug: Group 1|Drug: Group 2 | EMS | Phase 3 | 2012-09-01 | 2013-03-01 |
| NCT01125761 | Dermatitis | Drug: dexamethasone 0.5 mg and 1.0 mg clemastine cream|Drug: Dexamethasone 0,5 mg cream | Azidus Brasil | Phase 3 | 2010-11-01 | 2010-10-25 |
| NCT00481676 | Chronic Urticaria | Drug: Omalizumab 75-375 mg|Drug: Placebo to omalizumab|Drug: Loratadine|Drug: Clemastine | Novartis | Phase 2 | 2007-05-01 | 2011-09-14 |
| NCT01154361 | Angioedema | Drug: Icatibant (subcutaneous) and plazebo (intravenous)|Drug: Cortisone + Clemastin (intravenous) and plazebo (subcutaneous) | Technische Universit盲t M眉nchen | Phase 2 | null | 2011-12-22 |
